Tenaya Reports Positive TN-201 Gene Therapy Data in MYBPC3-Associated HCM
SOUTH SAN FRANCISCO, Calif., June 3, 2026 Tenaya Therapeutics announced new interim data from its ongoing MyPEAK™-1 Phase 1b/2...
Tenaya Therapeutics
Advertisement
Tenaya Therapeutics Prepares New TN-201 Gene Therapy Data for Genetic Heart Disease
SOUTH SAN FRANCISCO, Calif., June 2, 2026 Tenaya Therapeutics announced that it will present new interim clinical data from...
Tenaya Gene Therapy Shows Strong Arrhythmia Reduction in ARVC Trial
SOUTH SAN FRANCISCO, Calif., May 15, 2026 Tenaya Therapeutics reported encouraging interim Phase 1b/2 clinical data for TN-401, its...
Tenaya–Alnylam $1.13B Deal Targets Heart Disease Genes
South San Francisco, California — March 5, 2026 Tenaya Therapeutics and Alnylam Pharmaceuticals have announced a major research collaboration...
Advertisement
